Patterns of X-Linked Retinitis Pigmentosa Genetic Testing in England and Implications for Service Provision

Purpose: )-associated X-linked retinitis pigmentosa (XLRP) in England. Design: A cross-sectional prevalence study. Participants: English National Health Service patients referred for XLRP molecular testing between 2004 and 2024. Methods: -XLRP per 100 000 population (2024) in England. We also investigated trends in genetic testing over time and explored equity of access by region and socio-economic status through comparisons of absolute test numbers and testing rates per 100 000 population. Main Outcome Measures: -XLRP per 100 000 population, overall and stratified by region and Index of Multiple Deprivation (IMD) quintile. Results: -XLRP among males is 2.18 per 100 000 males (n = 626) and 1.17 per 100 000 females (n = 351) (2024). The mean age of test-positive patients was 44.1 years at study end date (2024). Population-standardized testing rates were broadly consistent across regions, with all regions falling within 19% of the national average, except the North West (34%), reflecting interregional referral patterns. Testing volumes (absolute numbers) per socio-economic quintile (IMD) were within 17% of the average. The number of individuals tested for ORF15 seemed to reduce after the introduction of whole genome sequencing (2019). Conclusions: -associated XLRP from 2594 tested individuals, representing a large absolute number and significant population who could benefit from emerging gene therapy, with prevalence higher than other treatable inherited retinal dystrophies. We found no systematic inequities in test access by socio-economic status or region, though a decline in testing since 2020 warrants further investigation. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Authors

Institutions

Publication Details

Journal
Ophthalmology Science
Published
2026-04-01
DOI
https://doi.org/10.1016/j.xops.2026.101180
Primary Topic
Retinal Development and Disorders
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patterns of X-Linked Retinitis Pigmentosa Genetic Testing in England and Implications for Service Provision

William Whittaker, Katherine Payne, Graeme C. Black, Sol Yates et al.
Ophthalmology Science
Retinal Development and Disorders
article

Patterns of X-Linked Retinitis Pigmentosa Genetic Testing in England and Implications for Service Provision

William Whittaker, Katherine Payne, Graeme C. Black, Sol Yates, Stephanie Barton, Stuart G. Bayliss, Panagiotis I. Sergouniotis
article en

Abstract

Purpose: )-associated X-linked retinitis pigmentosa (XLRP) in England. Design: A cross-sectional prevalence study. Participants: English National Health Service patients referred for XLRP molecular testing between 2004 and 2024. Methods: -XLRP per 100 000 population (2024) in England. We also investigated trends in genetic testing over time and explored equity of access by region and socio-economic status through comparisons of absolute test numbers and testing rates per 100 000 population. Main Outcome Measures: -XLRP per 100 000 population, overall and stratified by region and Index of Multiple Deprivation (IMD) quintile. Results: -XLRP among males is 2.18 per 100 000 males (n = 626) and 1.17 per 100 000 females (n = 351) (2024). The mean age of test-positive patients was 44.1 years at study end date (2024). Population-standardized testing rates were broadly consistent across regions, with all regions falling within 19% of the national average, except the North West (34%), reflecting interregional referral patterns. Testing volumes (absolute numbers) per socio-economic quintile (IMD) were within 17% of the average. The number of individuals tested for ORF15 seemed to reduce after the introduction of whole genome sequencing (2019). Conclusions: -associated XLRP from 2594 tested individuals, representing a large absolute number and significant population who could benefit from emerging gene therapy, with prevalence higher than other treatable inherited retinal dystrophies. We found no systematic inequities in test access by socio-economic status or region, though a decline in testing since 2020 warrants further investigation. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Ophthalmology ScienceVol. 6(6)
University of British Columbia (CA), University of Liverpool (GB), Manchester Academic Health Science Centre (GB), St. Paul's Hospital (CA), University of Manchester (GB), Manchester University NHS Foundation Trust (GB), St Mary's Hospital (GB), Genomics (United Kingdom) (GB)
Wellcome Trust, National Institute for Health and Care Research, Manchester Biomedical Research Centre, Janssen Pharmaceuticals
Openalex Percentile: Top 31%
Retinal Development and Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.